Yuyu Pharma: "Complex-Formulation Platform Technology 'YUNICAP' Registered as Trademark with KIPO"

Secures platform technology for combination drug development
Completes manufacturing process setup
Pushes to expand applications across various fields

Yuyu Pharma said on October 19 that it had completed development of YUNICAP, a complex-formulation platform technology that combines medicines in different dosage forms in a single capsule, and registered the trademark with the Korean Intellectual Property Office.

The name YUNICAP combines Yuyu, Uni (integration), and Polycap. It is a complex-formulation technology that combines different dosage forms, such as tablets, soft capsules, and pellets, inside a single hard capsule while keeping them separate. By compartmentalizing the ingredients and keeping them independent, the technology addresses the limitations of existing combination drugs based on a single tablet.

The technology can be used to create various combinations of dosage forms within a single hard capsule, including tablet + tablet, tablet + pellet, tablet + soft capsule, and soft capsule + pellet. Because each dosage form can be designed independently, the dissolution profile of each ingredient can be set individually. Minimizing direct contact between ingredients can also help address stability issues associated with combining them. Another advantage is that existing single-ingredient products can be used as they are, substantially reducing development time and process-related burdens.

Yuyu Pharma has completed manufacturing process setup at its Jecheon plant to enable production of products using YUNICAP technology. The company is currently developing a combination drug using the technology to treat benign prostatic hyperplasia, with a launch targeted for the second half of 2027.

The company is also pursuing a strategy to generate revenue through contract manufacturing and consignment production. It believes that the ability to develop differentiated products targeting niche markets, rather than simple generic drugs, will strengthen its competitiveness not only for its own products but also in its contract manufacturing and consignment businesses.

Kim Kyungwon, head of Yuyu Pharma's Central Research Institute, said, "YUNICAP is a highly valuable platform technology that can overcome the limitations of existing combination drugs and be used to design various dosage forms and develop combination drugs. We filed a trademark application immediately after completing development to proactively protect the value of our proprietary Polycap technology."

This content was produced with the assistance of AI translation services.